Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

NCT ID: NCT05099445

Last Updated: 2023-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-14
• Study Completion Date: 2023-02-27

Brief Summary

This is a multicenter, open-label parallel-group to evaluate single oral doses of INCB000928 in participants with varying level of renal function or impairment.

Conditions

Renal Impairment; Hemodialysis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group 1: Normal Renal Function

Participants with normal levels of renal function will receive a single oral dose of INCB000928 200 mg on Day 1.

Group Type: EXPERIMENTAL

INCB000928

Intervention Type: DRUG

INCB000928 200 mg will be administered on Day 1 of each treatment period.

Group 2: Mild Renal Impairment

Participants with mild levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.

Group Type: EXPERIMENTAL

INCB000928

Intervention Type: DRUG

INCB000928 200 mg will be administered on Day 1 of each treatment period.

Group 3: Moderate Renal Impairment

Participants with moderate levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.

Group Type: EXPERIMENTAL

INCB000928

Intervention Type: DRUG

INCB000928 200 mg will be administered on Day 1 of each treatment period.

Group 4: Severe Renal Impairment

Participants with severe levels of renal impairment will receive a single oral dose of INCB000928 200 mg on Day 1.

Group Type: EXPERIMENTAL

INCB000928

Intervention Type: DRUG

INCB000928 200 mg will be administered on Day 1 of each treatment period.

Group 5: Kidney Failure

Group 5 participants with ESRD maintained on HD will receive a single dose of INCB000928 on Day 1 of each of 2 treatment periods before (Period 1) and after (Period 2) an HD session in order to study the effects of HD on INCB000928.

Group Type: EXPERIMENTAL

INCB000928

Intervention Type: DRUG

INCB000928 200 mg will be administered on Day 1 of each treatment period.

Interventions

INCB000928

INCB000928 200 mg will be administered on Day 1 of each treatment period.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18 to 82 years (inclusive) at the time of signing the ICF.
• Participants will be classified at screening by renal function based on eGFR as calculated by the MDRD formula and requirement for HD (Group 5).
• Participants eligible for Group 5 with ESRD have received HD for at least 3 months prior to screening.
• Participants eligible for Group 1 should be in good health as determined by no clinically significant deviations from normal for medical history, physical examination, vital signs,12-lead ECGs, or clinical laboratory determinations at screening or Day -1.
• Participants eligible for Groups 2 through 5 may have medical findings consistent with their degree of renal dysfunction, as determined by medical history, physical examination, vital signs, 12-lead ECGs, and clinical laboratory determinations at screening and Day -1 (Groups 2 through 4) or Period 1, Day -1 (Group 5). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible.
• Body mass index within the range 18.0 to 40.0 kg/m2 (inclusive) at screening.
• Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
• Ability to swallow and retain oral medication.

Exclusion Criteria

• History of uncontrolled or unstable cardiovascular, respiratory, hepatic, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening.
• Evidence of rapidly deteriorating renal function.
• Participants who have a current, functioning organ transplant or have a scheduled organ transplant within 6 weeks after check-in.
• History of malignancy within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.
• History of clinically significant GI disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug.
• Participants eligible for Group 1 who have a history of renal disease or renal injury as indicated by an abnormal, clinically significant renal function profile at screening or Day -1.
• Participants eligible for Groups 2 through 5 who have had a change in disease status within 30 days of screening, as documented by the participant's medical history and deemed clinically significant by the investigator.
• History or current diagnosis of uncontrolled or significant cardiac disease indicating
• significant risk of safety for participation in the study, including any of the following:

1. Recent myocardial infarction (within 6 months of check-in).

2. New York Heart Association Class III or IV congestive heart failure.

3. Unstable angina (within 6 months of check-in).

4. Clinically significant (symptomatic) cardiac arrhythmias (eg, sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker).

5. Uncontrolled hypertension.

• Any major surgery within 4 weeks of screening.
• Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for
• plasma only).
• Blood transfusion within 4 weeks of Day -1 (for Groups 1 through 4) or Period 1,
• Day -1 (Group 5).
• Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
• Positive test and symptomatic for HBV, HCV, or HIV. Participants whose results are compatible with prior immunization for or immunity due to infection with HBV may be included at the discretion of the investigator.
• Participants eligible for Group 1 who have a history of using tobacco- or nicotine containing products within 6 months of screening.
• Participants eligible for Groups 2 through 5 who smoke > 10 cigarettes per day or equivalent use of other tobacco- or nicotine-containing products and are unwilling to refrain from tobacco or nicotine use on dosing days and abide by CRU restrictions.
• History of alcohol dependency within 3 months of screening.
• Positive breath test for ethanol or positive urine or saliva screen for drugs of abuse (confirmed by repeat) at screening or check-in that are not otherwise explained by permitted concomitant medications.
• Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with another investigational medication or current enrollment in another investigational drug study.
• Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with strong or moderate inducer or inhibitor of CYP3A4 or P-gp (refer to the Drug Interaction Database Program [University of Washington School of Pharmacy 2002] for prohibited drugs).
• Participants eligible for Group 1 who have used prescription drugs within 14 days of study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days of study drug administration. However, occasional acetaminophen and ibuprofen are permitted.
• Participants eligible for Groups 2 through 5 who have used prescription drugs within 14 days of study drug administration, with the exception of established therapy for renal disease and the treatment of associated disorders that have been stable for at least 7 days prior to study drug administration, as approved by the investigator and in consultation with the sponsor's medical monitor.
• Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics. Current clinically significant viral infection at screening or check-in.
• History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
• Inability to undergo venipuncture or tolerate venous access.
• Participants eligible for Group 5 who are not expected to continue HD treatment for the duration of the study.
• Receipt of live (including attenuated) vaccines within 3 months of check-in or
• anticipation of need for such a vaccine during the study (Note: nonlive or inactivated vaccines are allowed up to 2 weeks prior to the first dose of study drug).
• Known hypersensitivity or severe reaction to INCB000928 or excipients of INCB000928(refer to IB).
• Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
• Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits;pose a significant risk to the participant; or interfere with interpretation of study data.
• Women who are pregnant or breastfeeding.
• QTc > 450 milliseconds for Groups 1 through 3 and QTc > 470 milliseconds for Group 4.
• Participants eligible for Group 1 who have abnormal LFT values, defined as aspartate aminotransferase, alanine aminotransferase, and serum (total and direct) bilirubin, as well as amylase and lipase above the upper limit of the normal range at screening.
• Participants eligible for Groups 2 through 4 who have values outside the normal ranges for LFTs; however, values may be acceptable if they are consistent with the participant's renal condition (if stable for 1 month prior to screening) and if the investigator (or designee) and the sponsor feel that the results are not clinically significant (based on age and renal impairment status).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 82 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Incyte Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Inland Empire Liver Foundation

Rialto, California, United States

Clinical Pharmacology of Miami

Hialeah, Florida, United States

Advanced Pharma

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Nucleus Network Minneapolis Clinic

Saint Paul, Minnesota, United States

Countries

United States

Other Identifiers

INCB 00928-108

Identifier Type: -

Identifier Source: org_study_id